Abstracts tagged "Behçet’s Syndrome"

Abstract Number: L14 • ACR Convergence 2024
A Withdrawal Study of Colchicine in Behçet Syndrome
Basak Sirin¹, Sinem Nihal Esatoglu², Hasan Yazıcı³ and Gulen Hatemi⁴, ¹Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ²Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, ³Academic Hospital, Istanbul, Turkey, ⁴Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey
Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
Abstract Number: 0150 • ACR Convergence 2024
The Characteristics of a Northern Israeli Cohort of Patients with Behcet’s Syndrome
Firas Sabbah¹, Fadi Hassan², Rula Daood², Helana Jeries³, Tamar Hareuveni⁴, Nimer Abed⁵ and Mohammad E Naffaa², ¹Rheumatology Unit, Tzafon Medical Center, Poria, Israel, Tiberias, Israel, ²Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, ³Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, ⁴Ophthalmology department, Galilee Medical Center, Naharyia, Israel, Nahariya, Israel, ⁵Internal Medicine "B", Galilee Medical Center, Naharyia, Israel, Nahariya
Background/Purpose: Behcet's syndrome (BS) is a multisystem disease that typically manifests as recurrent oral and genital ulcers, along with skin, eye, gastrointestinal, neurologic and vascular…
Abstract Number: 1111 • ACR Convergence 2024
Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Kessiena Aomreore, Lincoln Medical Center, New york, NY
Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
Abstract Number: 1118 • ACR Convergence 2024
The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Muhammad Shamim¹, Mazen Allouni², Haseeb Chaudhary³ and Omer Pamuk⁴, ¹University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ²Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ³Case Western Reserve University, Westlake, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
Abstract Number: 1633 • ACR Convergence 2024
Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients
Koichi Sugihara¹, Risa Wakiya², Hiromi Shimada², Taichi Miyagi², Yusuke Ushio², Rina Mino², Mao Mizusaki³, Hayamasa yamaguchi³, Naoto Manabe³, Shusaku Nakashima² and Hiroaki dobashi², ¹Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, ²Kagawa University, Miki-cho, Kita-gun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan
Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…
Abstract Number: 1896 • ACR Convergence 2024
The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics
Priyanka Chandratre¹, Joht Chandan², Ben Hammond³, Rasiah Thayakaran³, Samuel Cusworth³, Nicola Adderley³ and Deva Situnayake⁴, ¹The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, ²Institute of Applied Health Research, Birmingham, United Kingdom, ³Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, ⁴Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom
Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
Abstract Number: 2515 • ACR Convergence 2024
Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study
Weiyi Xia¹, Jiachen Li¹, Tian Liu¹ and Yuhui Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University, BeiJing, China
Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
Abstract Number: 2517 • ACR Convergence 2024
Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome
Betul Sarac¹, Ayse Kalkanci², Esra Kilic², Elif Ayca Sahin², Yesim Ozguler³ and Gulen Hatemi³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ²Gazi University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Gut, oral and genital mucosa microbiome studies in Behçet’s syndrome have shown heterogeneous results including reduced bacterial diversity and decrease in butyrate-producing bacteria. A…
Abstract Number: 2518 • ACR Convergence 2024
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Yesim Ozguler¹, Olivier Manches², Didar Ucar³, Ziyan Lin², Alireza Khodadadi-Jamayran², Aristotelis Tsirigos², Gulen Hatemi¹ and Johannes Nowatzky⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²NYU Grossman School of Medicine, New York, NY, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
Abstract Number: 2522 • ACR Convergence 2024
Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event
Kerem Abacar¹, Ayşe Elif Boncukcuoğlu¹, Aysun Aksoy², Derya Kocakaya¹, Çagatay Cimşit¹, Haner Direskeneli³ and Fatma Alibaz Öner³, ¹Marmara University, istanbul, Turkey, ²Alaaddin Keykubat University, Antalya, Turkey, ³Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
Abstract Number: 2524 • ACR Convergence 2024
Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis
Sooah Kim¹, Ye Ji Jung², Joong Kyong Ahn³ and Jiwon Hwang⁴, ¹Environment Science & Biotechnology, Jeonju University, Jeonju, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, ³Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁴Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea
Background/Purpose: Oral manifestations can be the initial indicators of systemic diseases such as Behcet’s disease (BD) and Sjogren’s syndrome (PSS). The frequency and presentation of…
Abstract Number: 0692 • ACR Convergence 2023
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Johannes Nowatzky¹, Ziyan Lin², Yesim Ozguler³, Alireza Khodadadi-Jamayran², Didar Ucar⁴, Aristotelis Tsirigos⁵, Gulen Hatemi⁶ and Olivier Manches⁷, ¹NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, ²NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁵NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France
Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
Abstract Number: 1564 • ACR Convergence 2023
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease
fatma Alibaz-Öner¹, Rabia Ergelen², Seda Kutluğ Ağaçkıran³, Fatma Temiz⁴, Tulin Ergun⁵ and Haner Direskeneli⁶, ¹Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Marmara University, School of Medicine, Department of Radiology, Istanbul, Turkey, ³Marmara University, School of Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁵Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁶Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey
Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on multi-systemic clinical manifestations after ruling out other potential causes. There is no specific diagnostic…
Abstract Number: 0701 • ACR Convergence 2023
Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Fabricio Benavides¹, Alba Herrero-Morant², Jose Luis Martin-Varillas³, Carmen Alvarez Reguera¹, Lara Sanchez-Bilbao⁴, David Martinez-Lopez⁵, Raul Fernandez¹, Ivan Ferraz Amaro⁶, Jose Luis Hernandez¹ and Ricardo Blanco⁷, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Hospital de Sierrallana, Santander, Spain, ⁶Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Behçet’s Disease (BD) incidence varies widely worldwide. Neurobehcet’s disease (NBD) is one of the most severe manifestations of BD. Data on NBD incidence is…
Abstract Number: 2517 • ACR Convergence 2023
The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease
Erdem Bektas¹, Rabia Deniz², Zeliha Emrence³, Sema Sırma Ekmekci³, Neslihan Abacı³, Shirkhan Amikishiyev⁴, Yasemin Yalçınkaya⁴, Bahar Artim Esen⁴, Murat Inanç⁵ and Ahmet Gul⁶, ¹Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey, ²University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Rheumatology, Istanbul, Turkey, ³Istanbul University, Aziz Sancar Institute of Experimental Medicine, Department of Genetics, Istanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
Background/Purpose: Behcet disease (BD) is a multisystemic inflammatory disease of unknown etiology. BD has been classified among the neutrophilic dermatosis, and neutrophil extracellular traps (NETs)…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].